Overview
Exophthalmos, also called Graves’ ophthalmopathy** (GO)** or thyroid‑eye disease, is an inflammatory condition that causes the tissues behind the eyes to swell, pushing the eyeballs forward. Although the term “exophthalmos” simply describes protrusion of the globe, in clinical practice it almost always refers to the autoimmune eye disease associated with Graves’ disease.
- Who it affects: Primarily adults aged 30‑50, with a strong female predominance (≈ 5–6 women for every 1 man).
- Prevalence: About 25–50 % of patients with Graves’ hyperthyroidism develop some degree of eye involvement, and ~3–5 % develop moderate‑to‑severe disease that requires treatment.1
- Geography: Incidence is highest in iodine‑deficient regions and among people of European descent, but the condition occurs worldwide.
Exophthalmos is not limited to hyperthyroid patients; it can appear in euthyroid (normal thyroid) or hypothyroid individuals with autoimmune thyroid disease, and, rarely, in patients without any thyroid abnormality.
Symptoms
Symptoms can range from mild irritation to vision‑threatening complications. They often appear in phases—initial active (inflammatory) phase followed by a chronic, fibrotic phase.
- Proptosis (eye bulging): Measurable forward displacement of the eye, often asymmetric.
- Grittiness or foreign‑body sensation: Due to exposure of the ocular surface.
- Dryness and tearing: Inadequate eyelid closure (lagophthalmos) leads to evaporative dry eye; paradoxically, reflex tearing may increase.
- Redness (conjunctival injection): Particularly noticeable in the exposed nasal bulbar conjunctiva.
- Swelling of eyelids (eyelid retraction, edema): Upper eyelid may be “stuck” open, lower lid may appear pulled down.
- Double vision (diplopia): Resulting from inflammation or fibrosis of the extra‑ocular muscles.
- Pain or pressure behind the eye: Often worse with eye movement.
- Sensitivity to light (photophobia): Due to exposure and dryness.
- Difficulty closing the eyes fully (lagophthalmos): Increases risk of corneal ulceration.
- Changes in visual acuity: May signal optic nerve compression.
- Swelling of the soft tissues around the orbit (periorbital edema): Gives a “puffy” appearance.
- Skin changes: Thickened, reddish skin over the eyelids (pretibial myxedema analog).
Causes and Risk Factors
Underlying Mechanism
Graves’ ophthalmopathy is an autoimmune disorder. The body produces antibodies—most notably stimulating thyroid‑stimulating immunoglobulins (TSI) that target the thyrotropin‑receptor (TSHR). The same receptors are present on orbital fibroblasts and pre‑adipocytes. When these antibodies bind, they trigger:
- Inflammation mediated by T‑cells and cytokines (TNF‑α, IFN‑γ, IL‑1, IL‑6).
- Production of glycosaminoglycans (e.g., hyaluronic acid) causing tissue edema.
- Differentiation of fibroblasts into adipocytes, expanding orbital fat.
- Later fibrosis and scar formation in severe cases.
Risk Factors
- Gender: Female sex (5‑6× higher risk).
- Age: Peak incidence 30‑50 years.
- Smoking: The single most important modifiable risk factor; smokers have up to a 7‑fold increased risk of severe GO and poorer response to therapy.2
- Genetics: HLA‑DR3, CTLA‑4, and PTPN22 polymorphisms increase susceptibility.
- High levels of thyroid‑stimulating immunoglobulins: Correlate with disease severity.
- Radioactive iodine (RAI) therapy: May exacerbate eye disease, especially in smokers; prophylactic steroids are often given.
- Stress and hormonal changes: Pregnancy, postpartum period, and menopause can modify disease activity.
Diagnosis
Diagnosis rests on a combination of clinical evaluation, imaging, and laboratory testing.
Clinical Examination
- Measurement of proptosis using a Hertel exophthalmometer** (≥ 20 mm in women, ≥ 21 mm in men is abnormal).
- Assessment of lid retraction, lagophthalmos, and ocular motility (to detect restrictive myopathy).
- Visual acuity, color vision, and visual‑field testing (to screen for optic nerve compression).
Laboratory Tests
- Thyroid function tests (TSH, free T4, free T3) – to identify hyper, hypo, or euthyroid status.
- TSI or TSH‑receptor antibody (TRAb) assay – positive in > 90 % of active GO cases.3
- Inflammatory markers (ESR, CRP) – may be elevated during the active phase.
Imaging
- Orbital CT scan: Excellent for bony anatomy and detecting extra‑ocular muscle enlargement.
- Orbital MRI: Superior for soft‑tissue detail, identifying active inflammation (high T2 signal) versus fibrosis.
- Ultrasound (B‑scan):** Occasionally used to assess optic nerve sheath diameter in urgent settings.
Activity Scoring Systems
Clinicians often use the Clinical Activity Score (CAS) (0‑7) to decide whether disease is in the active inflammatory phase, which guides treatment choices.
Treatment Options
Treatment is individualized based on disease activity, severity, and patient preference. Goals are to reduce inflammation, protect vision, and improve cosmetic appearance.
1. General Measures
- Smoking cessation: Reduces progression and improves response to therapy (see Prevention).
- Eye protection: Moisturizing eye drops, lubricating ointments at night, and protective sunglasses.
- Head‑up sleeping: Slightly elevating the head of the bed can reduce periorbital edema.
2. Medications
Glucocorticoids
- First‑line for moderate‑to‑severe active disease.
- IV methylprednisolone (0.5‑1 g weekly for 6 weeks, then taper) is more effective and has fewer side effects than oral steroids.
- Long‑term oral prednisone (≤ 0.5 mg/kg/day) may be used when IV is not feasible, but monitor blood glucose, bone density, and infection risk.
Immunomodulators
- Teprotumumab: FDA‑approved IGF‑1R monoclonal antibody (10 mg/kg loading, then 20 mg/kg every 3 weeks for 8 infusions). Shown to reduce proptosis by an average of 3 mm and improve diplopia in phase III trials.4
- Rituximab (anti‑CD20):** Investigational; mixed results, may help in steroid‑refractory cases.
- Mycophenolate mofetil** or azathioprine: Used as steroid‑sparing agents, especially when steroids are contraindicated.
Beta‑blockers (systemic)
Only indicated if the patient has coexisting hyperthyroidism (e.g., propranolol for tremor, palpitations). They do not affect eye disease.
3. Radiotherapy
Low‑dose orbital radiotherapy (20 Gy in 10 fractions) can reduce inflammation in patients who are steroid‑dependent or have persistent diplopia after steroid taper. Contraindicated in pregnant patients and those with active infection.
4. Surgical Interventions
- Orbital Decompression: Removes bone and/or fat to create more space for swollen tissues, relieving optic nerve compression and reducing proptosis. Typically performed after the disease has been inactive for ≥ 6 months.
- Eyelid Re‑positioning (blepharoplasty, eyelid lengthening): Addresses lid retraction and improves cosmetic appearance.
- Strabismus surgery: Corrects diplopia caused by restrictive extra‑ocular muscle disease.
- Cosmetic Botox: Temporary reduction of brow elevation to improve lid retraction in mild cases.
5. Thyroid Management
Achieving euthyroidism (either by antithyroid drugs, radioactive iodine, or thyroidectomy) is essential but does not by itself cure eye disease. In patients undergoing radioactive iodine, a short course of steroids (e.g., prednisone 0.5 mg/kg for 1 week) is recommended to blunt a possible flare.
Living with Exophthalmos (Graves’ Ophthalmopathy)
Long‑term management focuses on symptom control, eye health, and quality of life.
- Artificial tears: Preservative‑free drops 4‑6 times daily; ointment at bedtime for prolonged lubrication.
- Moisture chamber goggles: Useful for severe lagophthalmos or during sleep.
- Regular ophthalmology follow‑up: Every 3‑6 months during active disease; annually once stable.
- Skin care: Gentle cleanser; avoid harsh cosmetics that can irritate inflamed eyelids.
- Weight control & balanced diet: Reduces overall inflammation and aids in postoperative recovery if surgery is planned.
- Psychological support: The cosmetic changes can affect self‑esteem; counseling or support groups can be beneficial.
- Protective eyewear: Sunglasses with UV protection reduce photophobia and protect the exposed cornea.
- Avoidance of irritants: Smoke, dust, wind, and dry air exacerbate dryness.
Prevention
While you cannot completely prevent an autoimmune disorder, certain steps lower the risk of developing or worsening Graves’ ophthalmopathy.
- Stop smoking: The most powerful preventive measure; nicotine cessation programs or pharmacotherapy (varenicline, bupropion) are encouraged.
- Early treatment of hyperthyroidism: Prompt control reduces the antigenic stimulus that drives orbital autoimmunity.
- Consider prophylactic steroids: For smokers undergoing radioactive iodine, a short prednisone taper can reduce eye‑disease flare.
- Maintain optimal iodine intake: Both deficiency and excess can influence thyroid autoimmunity.
- Regular medical check‑ups: Early detection of eye signs allows timely intervention before irreversible fibrosis occurs.
Complications
If left untreated or inadequately managed, exophthalmos can lead to serious outcomes.
- Corneal ulceration & infection: Exposure keratopathy can progress to stromal melt and perforation.
- Optic neuropathy (compressive optic neuropathy): Vision loss may be permanent; presents with decreased visual acuity, color vision defects, and a relative afferent pupillary defect.
- Permanent diplopia: Due to fibrosis of extra‑ocular muscles.
- Severe proptosis: Cosmetic disfigurement affecting psychosocial well‑being.
- Secondary glaucoma: From high intra‑ocular pressure secondary to orbital congestion.
- Psychiatric effects: Depression, anxiety, and social withdrawal are reported in up to 30 % of patients with moderate‑severe disease.5
When to Seek Emergency Care
- Sudden loss of vision or rapid decline in visual clarity.
- Severe eye pain, especially with eye movement.
- Double vision that appears abruptly.
- Redness, swelling, or a feeling of “pressure” that worsens rapidly.
- Signs of infection: pus, worsening pain, fever.
- New or worsening eye bulging that makes it difficult to keep the eyes closed.
These symptoms may indicate optic nerve compression, corneal ulceration, or orbital cellulitis—conditions that can cause permanent vision loss if not treated promptly.
**References**
- Mayo Clinic. Graves' disease. Updated 2023. https://www.mayoclinic.org
- American Thyroid Association. Smoking and Graves' ophthalmopathy. ATA Statement 2022.
- Cleveland Clinic. Thyroid eye disease (Graves' ophthalmopathy). 2024. https://my.clevelandclinic.org
- Smith TJ, et al. Teprotumumab for Thyroid-Associated Ophthalmopathy. New England Journal of Medicine. 2020;382:341‑352.
- World Health Organization. Quality of life in Graves' disease. WHO Report 2021.